{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 2-(2-(4-((1''Z'')-4-Chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol
| image = Fispemifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 341524-89-8
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9954033
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 8129643
| UNII = 3VZ2833V08
| KEGG = D10008
| ChEBI = 
| ChEMBL = 2107341

<!--Chemical data-->
| C=26 | H=27 | Cl=1 | O=3
| molecular_weight = 422.9493 g/mol
| SMILES = C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCOCCO)/CCCl
| StdInChI_Ref = 
| StdInChI = 1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25-
| StdInChIKey_Ref = 
| StdInChIKey = NKZTZAQIKKGTDB-QPLCGJKRSA-N
| synonyms = HM-101
}}

'''Fispemifene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''HM-101''') is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group that was developed for the treatment of male [[hypogonadism]] but was abandoned and never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800013715{{dead link|date=January 2017|bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name="CanoAlsina2006">{{cite book|author1=Antonio Cano|author2=Joacquim Calaf i Alsina|author3=Jose Luis Duenas-Diez|title=Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs|url=https://books.google.com/books?id=heJDAAAAQBAJ&pg=PA52|date=22 September 2006|publisher=Springer Science & Business Media|isbn=978-3-540-34742-2|pages=52–}}</ref><ref name="OttowWeinmann2008">{{cite book|author1=Eckhard Ottow|author2=Hilmar Weinmann|title=Nuclear Receptors as Drug Targets|url=https://books.google.com/books?id=iATfLbPgRugC&pg=PA90|date=8 September 2008|publisher=John Wiley & Sons|isbn=978-3-527-62330-3|pages=90–}}</ref> It reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for this indication before development was terminated in March 2016.<ref name="AdisInsight" /> The drug failed to achieve [[statistical significance]] on key [[effectiveness]] [[clinical endpoint|endpoint]]s in clinical trials and was discontinued by its developer for strategic reasons.<ref name="AdisInsight" />

==See also==
* [[Ospemifene]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800013715 Fispemifene - AdisInsight]

{{Estrogen receptor modulators}}
{{Use dmy dates|date=April 2017}}

[[Category:Alcohols]]
[[Category:Organochlorides]]
[[Category:Progonadotropins]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]


{{genito-urinary-drug-stub}}